Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078411 | 0.79 | CYP3A4 (0.44) | HDAC1PIK3CAPIK3R1CYP3A4PDE10A | |
| SCHEMBL2396728 | 0.77 | CYP3A4 (0.45) | HDAC1PIK3CAPIK3R1CYP3A4PDE10A | |
| SCHEMBL16542529 | 0.75 | HDAC1 (0.35) | HDAC1PIK3CAPIK3R1CYP3A4PDE10A | |
| SCHEMBL19946564 | 0.75 | PIK3CD (0.44) | HDAC1PIK3CAPIK3R1P2RX3CYP3A4 | |
| SCHEMBL17087371 | 0.75 | HDAC1 (0.63) | HDAC1PIK3CAPIK3R1HDAC2HDAC8 | |
| SCHEMBL17087486 | 0.75 | PIK3CA (0.58) | HDAC1PIK3CAPIK3R1HDAC2HDAC8 | |
| SCHEMBL25232616 | 0.73 | PIK3CD (0.44) | HDAC1PIK3CAPIK3R1P2RX3CYP3A4 | |
| SCHEMBL18518046 | 0.72 | PIK3CD (0.44) | HDAC1PIK3CAPIK3R1P2RX3CYP3A4 | |
| SCHEMBL25226620 | 0.71 | CYP3A4 (0.48) | HDAC1CYP3A4PDE10A | |
| SCHEMBL2396203 | 0.70 | POLB (0.42) | HDAC1PIK3CAPIK3R1CYP3A4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885PIK3CA 321/4885PIK3R1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.